Clinical trial

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

NCT04989322

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2021-10-05

PhasePHASE2

Study timeline

Study start (actual)2021-10-05Date precision: day

Registry last updated2021-12-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Nsclcunresolved

EGFR Activating Mutationunresolved

EGF-R Positive Non-Small Cell Lung Cancerunresolved

ALK Gene Rearrangement Positiveunresolved

ROS1 Gene Rearrangementunresolved

ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung Cancerunresolved

Interventions

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

LenvatinibDRUG · verified · RxNorm: lenvatinib

PemetrexedDRUG · verified · RxNorm: pemetrexed

CarboplatinDRUG · verified · RxNorm: carboplatin

Sponsors & collaborators

Dr Joanne CHIUlead sponsor

Mapped research locations

Hong KongHong Kong1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04989322 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.